M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

A Phase 3, Multi-Center, Double-Blind, Randomized, Efficacy and Safety Study of M108 Monoclonal Antibody Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Gastric/GEJ adenocarcinoma, which is one of the major leading causes of cancer-related deaths worldwide, is a global challenge to human health. However, standard chemotherapy has limited efficacy in advanced gastric cancer, and there is an urgent need to explore and develop new therapeutic targets and combination therapy modalities. The main purpose of this study is to explore the efficacy of M108 monoclonal antibody plus capecitabine and oxaliplatin (CAPOX) versus placebo plus CAPOX as first-line treatment measured by progression free survival (PFS). This study will also evaluate safety, tolerability, pharmacokinetics and the immunogenicity profile of M108 monoclonal antibody, as well as its effects on quality of life.

Study Overview

• Status: Recruiting
• Conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
• Intervention / Treatment: Drug: M108 monoclonal antibody; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Placebo

Detailed Description

The aim of this phase 3, double-blind, randomized, placebo-controlled study is to explore the efficacy and safety of M108 monoclonal antibody plus chemotherapy versus placebo plus chemotherapy as first-line treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, locally advanced or metastatic gastric/GEJ adenocarcinoma. Patients will be randomized in a 1:1 ration to receive M108 monoclonal antibody plus chemotherapy or placebo plus chemotherapy.

• Study Type: Interventional
• Enrollment (Estimated): 486
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Zhaoyu Jin, Ph.D; Phone Number: 010-60709130; Email: pr@futuregenbiopharm.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100142
      • Recruiting
      • Beijing Cancer Hospital
      • Principal Investigator: Lin Shen, PHD
      • Contact: Lin Shen, PhD; Phone Number: 010-88196358; Email: doctorshenlin@sina.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Written informed consent
2. Histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma with no treatment previously. For patients with neoadjuvant/adjuant chemotherapy in the past, duration of last therapy to recurrence should be more than 6 months
3. At least 1 measurable site of the disease according to RECIST 1.1 criteria.
4. Positive CDLN 18.2 expression
5. Negative HER2 expression, PD-L1 CPS<5
6. ECOG performance status (PS) 0-1
7. Life expectancy > 3 months
8. Age ≥ 18 years and ≤75 years
9. Adequate haematological/ coagulation/ hepatic/ renal function
10. Men and women of childbearing age should agree to use effective contraception from the time they sign their informed consent until 3 months after the last dosing. Female subjects of childbearing age must have a negative blood beta-HCG test within 72 hours prior to first dosing.

Exclusion Criteria:

1. Previous radiotherapy within 4 weeks prior to the start of study treatment. (if palliative radiotherapy was given to bone metastases and the patient recovered from acute toxicity was allowed).
2. Previous anti-tumor therapy within 4 weeks prior to the start of study treatment.
3. Previous major operation within 4 weeks prior to the start of study treatment.
4. Have a prior severe allergic reaction or intolerance to known components of M108 monoclonal antibodies or other monoclonal antibodies (including humanized or chimeric antibodies); Allergic or intolerant to any component of capecitabine, oxaliplatin, etc.
5. Subject who has been treated with CLDN18.2 monoclonal/bispecific antibodies, CLDN18.2 CAR-T, CLDN18.2 ADC and any therapies that target CLDN18.2.
6. Subject who is in pregnant or in lactation period.
7. Other clinically significant disease which may have adversely affected the safe delivery of treatment within this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: M108 plus CAPOX	Drug: M108 monoclonal antibody; M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion.; Drug: Oxaliplatin; Oxaliplatin will be administered as a 2-hour IV infusion.; Drug: Capecitabine; Capecitabine will be administered orally twice daily (bid).
Placebo Comparator: placebo plus CAPOX	Drug: Oxaliplatin; Oxaliplatin will be administered as a 2-hour IV infusion.; Drug: Capecitabine; Capecitabine will be administered orally twice daily (bid).; Drug: Placebo; Placebo will be administered as a minimum 2-hour IV infusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival (PFS)	Compare PFS (Based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 by Independent Review Committee (IRC)) of patients treated with M108 monoclonal antibody or placebo plus CAPOX.	From date of randomization to the date of disease progression, death or end of study, assessed up to 24 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	Compare OS (Based on RECIST 1.1 by IRC) of patients treated with M108 monoclonal antibody or placebo plus CAPOX.	From date of randomization to the date of death or end of study, assessed up to 24 months
Safety and tolerability assessed by adverse events (AEs)	An AE is any adverse medical event that occurs during a clinical study, whether or not related with medicinal product, including signs, symptoms, abnormal laboratory test results and diseases. The incidence and severity of AEs during the clinical study are recorded and analyzed.	From date of randomization until 28+7 days after the last dose

Collaborators and Investigators

• Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): December 25, 2023
• Primary Completion (Estimated): January 11, 2027
• Study Completion (Estimated): April 11, 2027

Study Registration Dates

• First Submitted: December 11, 2023
• First Submitted That Met QC Criteria: December 11, 2023
• First Posted (Actual): December 20, 2023

Study Record Updates

• Last Update Posted (Actual): February 28, 2024
• Last Update Submitted That Met QC Criteria: February 25, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunologic Factors; Antibodies; Capecitabine; Oxaliplatin; Antibodies, Monoclonal
• Other Study ID Numbers: FG-M108-04

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No